↑Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA (1998). „Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice”. Endocr. Rev.19 (3): 225–68. DOI:10.1210/er.19.3.225. PMID9626554.
↑Sarkar S, Pollack BP, Lin KT, Kotenko SV, Cook JR, Lewis A, Pestka S (2001). „hTid-1, a human DnaJ protein, modulates the interferon signaling pathway”. J. Biol. Chem.276 (52): 49034–42. DOI:10.1074/jbc.M103683200. PMID11679576.
↑Olayioye MA, Beuvink I, Horsch K, Daly JM, Hynes NE (1999). „ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases”. J. Biol. Chem.274 (24): 17209–18. DOI:10.1074/jbc.274.24.17209. PMID10358079.
↑Huang LJ, Constantinescu SN, Lodish HF (2001). „The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor”. Mol. Cell8 (6): 1327–38. DOI:10.1016/S1097-2765(01)00401-4. PMID11779507.
↑Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O, Ihle JN (1993). „JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin”. Cell74 (2): 227–36. DOI:10.1016/0092-8674(93)90414-L. PMID8343951.
↑Sayeski PP, Ali MS, Safavi A, Lyles M, Kim SO, Frank SJ, Bernstein KE (1999). „A catalytically active Jak2 is required for the angiotensin II-dependent activation of Fyn”. J. Biol. Chem.274 (46): 33131–42. DOI:10.1074/jbc.274.46.33131. PMID10551884.
↑Giorgetti-Peraldi S, Peyrade F, Baron V, Van Obberghen E (1995). „Involvement of Janus kinases in the insulin signaling pathway”. Eur. J. Biochem.234 (2): 656–60. DOI:10.1111/j.1432-1033.1995.656_b.x. PMID8536716.
↑Frank SJ, Yi W, Zhao Y, Goldsmith JF, Gilliland G, Jiang J, Sakai I, Kraft AS (1995). „Regions of the JAK2 tyrosine kinase required for coupling to the growth hormone receptor”. J. Biol. Chem.270 (24): 14776–85. DOI:10.1074/jbc.270.24.14776. PMID7540178.
↑VanderKuur JA, Wang X, Zhang L, Campbell GS, Allevato G, Billestrup N, Norstedt G, Carter-Su C (1994). „Domains of the growth hormone receptor required for association and activation of JAK2 tyrosine kinase”. J. Biol. Chem.269 (34): 21709–17. PMID8063815.
↑Hellgren G, Jansson JO, Carlsson LM, Carlsson B (1999). „The growth hormone receptor associates with Jak1, Jak2 and Tyk2 in human liver”. Growth Horm. IGF Res.9 (3): 212–8. DOI:10.1054/ghir.1999.0111. PMID10502458.
↑Gual P, Baron V, Lequoy V, Van Obberghen E (1998). „Interaction of Janus kinases JAK-1 and JAK-2 with the insulin receptor and the insulin-like growth factor-1 receptor”. Endocrinology139 (3): 884–93. DOI:10.1210/endo.139.3.5829. PMID9492017.
↑Yamamoto K, Shibata F, Miura O, Kamiyama R, Hirosawa S, Miyasaka N (1999). „Physical interaction between interleukin-12 receptor beta 2 subunit and Jak2 tyrosine kinase: Jak2 associates with cytoplasmic membrane-proximal region of interleukin-12 receptor beta 2 via amino-terminus”. Biochem. Biophys. Res. Commun.257 (2): 400–4. DOI:10.1006/bbrc.1999.0479. PMID10198225.
↑Ogata N, Kouro T, Yamada A, Koike M, Hanai N, Ishikawa T, Takatsu K (1998). „JAK2 and JAK1 constitutively associate with an interleukin-5 (IL-5) receptor alpha and betac subunit, respectively, and are activated upon IL-5 stimulation”. Blood91 (7): 2264–71. PMID9516124.
↑ 16,016,116,2Fuhrer DK, Yang YC (1996). „Complex formation of JAK2 with PP2A, P13K, and Yes in response to the hematopoietic cytokine interleukin-11”. Biochem. Biophys. Res. Commun.224 (2): 289–96. DOI:10.1006/bbrc.1996.1023. PMID8702385.
↑Zhu T, Goh EL, Lobie PE (1998). „Growth hormone stimulates the tyrosine phosphorylation and association of p125 focal adhesion kinase (FAK) with JAK2. Fak is not required for stat-mediated transcription”. J. Biol. Chem.273 (17): 10682–9. DOI:10.1074/jbc.273.17.10682. PMID9553131.
↑Ryu H, Lee JH, Kim KS, Jeong SM, Kim PH, Chung HT (2000). „Regulation of neutrophil adhesion by pituitary growth hormone accompanies tyrosine phosphorylation of Jak2, p125FAK, and paxillin”. J. Immunol.165 (4): 2116–23. DOI:10.4049/jimmunol.165.4.2116. PMID10925297.
↑Yin T, Shen R, Feng GS, Yang YC (1997). „Molecular characterization of specific interactions between SHP-2 phosphatase and JAK tyrosine kinases”. J. Biol. Chem.272 (2): 1032–7. DOI:10.1074/jbc.272.2.1032. PMID8995399.
↑Tauchi T, Damen JE, Toyama K, Feng GS, Broxmeyer HE, Krystal G (1996). „Tyrosine 425 within the activated erythropoietin receptor binds Syp, reduces the erythropoietin required for Syp tyrosine phosphorylation, and promotes mitogenesis”. Blood87 (11): 4495–501. PMID8639815.
↑Maegawa H, Kashiwagi A, Fujita T, Ugi S, Hasegawa M, Obata T, Nishio Y, Kojima H, Hidaka H, Kikkawa R (1996). „SHPTP2 serves adapter protein linking between Janus kinase 2 and insulin receptor substrates”. Biochem. Biophys. Res. Commun.228 (1): 122–7. DOI:10.1006/bbrc.1996.1626. PMID8912646.
↑Wu DW, Stark KC, Dunnington D, Dillon SB, Yi T, Jones C, Pelus LM (2000). „SH2-Containing protein tyrosine phosphatase-1 (SHP-1) association with Jak2 in UT-7/Epo cells”. Blood Cells Mol. Dis.26 (1): 15–24. DOI:10.1006/bcmd.2000.0273. PMID10772872.
↑Pollack BP, Kotenko SV, He W, Izotova LS, Barnoski BL, Pestka S (1999). „The human homologue of the yeast proteins Skb1 and Hsl7p interacts with Jak kinases and contains protein methyltransferase activity”. J. Biol. Chem.274 (44): 31531–42. DOI:10.1074/jbc.274.44.31531. PMID10531356.
↑Xie S, Lin H, Sun T, Arlinghaus RB (2002). „Jak2 is involved in c-Myc induction by Bcr-Abl”. Oncogene21 (47): 7137–46. DOI:10.1038/sj.onc.1205942. PMID12370803.
↑VanderKuur J, Allevato G, Billestrup N, Norstedt G, Carter-Su C (1995). „Growth hormone-promoted tyrosyl phosphorylation of SHC proteins and SHC association with Grb2”. J. Biol. Chem.270 (13): 7587–93. DOI:10.1074/jbc.270.13.7587. PMID7535773.
↑Giordano V, De Falco G, Chiari R, Quinto I, Pelicci PG, Bartholomew L, Delmastro P, Gadina M, Scala G (1997). „Shc mediates IL-6 signaling by interacting with gp130 and Jak2 kinase”. J. Immunol.158 (9): 4097–103. PMID9126968.
↑Sasaki A, Yasukawa H, Shouda T, Kitamura T, Dikic I, Yoshimura A (2000). „CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2”. J. Biol. Chem.275 (38): 29338–47. DOI:10.1074/jbc.M003456200. PMID10882725.
↑Sasaki A, Yasukawa H, Suzuki A, Kamizono S, Syoda T, Kinjyo I, Sasaki M, Johnston JA, Yoshimura A (1999). „Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain”. Genes Cells4 (6): 339–51. DOI:10.1046/j.1365-2443.1999.00263.x. PMID10421843.
↑ 31,031,1Masuhara M, Sakamoto H, Matsumoto A, Suzuki R, Yasukawa H, Mitsui K, Wakioka T, Tanimura S, Sasaki A, Misawa H, Yokouchi M, Ohtsubo M, Yoshimura A (1997). „Cloning and characterization of novel CIS family genes”. Biochem. Biophys. Res. Commun.239 (2): 439–46. DOI:10.1006/bbrc.1997.7484. PMID9344848.
↑ 32,032,1Barahmand-Pour F, Meinke A, Groner B, Decker T (1998). „Jak2-Stat5 interactions analyzed in yeast”. J. Biol. Chem.273 (20): 12567–75. DOI:10.1074/jbc.273.20.12567. PMID9575217.
↑ 33,033,1Fujitani Y, Hibi M, Fukada T, Takahashi-Tezuka M, Yoshida H, Yamaguchi T, Sugiyama K, Yamanaka Y, Nakajima K, Hirano T (1997). „An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT”. Oncogene14 (7): 751–61. DOI:10.1038/sj.onc.1200907. PMID9047382.
↑Takeshita T, Arita T, Higuchi M, Asao H, Endo K, Kuroda H, Tanaka N, Murata K, Ishii N, Sugamura K (1997). „STAM, signal transducing adaptor molecule, is associated with Janus kinases and involved in signaling for cell growth and c-myc induction”. Immunity6 (4): 449–57. DOI:10.1016/S1074-7613(00)80288-5. PMID9133424.
↑Dif F, Saunier E, Demeneix B, Kelly PA, Edery M (2001). „Cytokine-inducible SH2-containing protein suppresses PRL signaling by binding the PRL receptor”. Endocrinology142 (12): 5286–93. DOI:10.1210/en.142.12.5286. PMID11713228.
↑Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, Miyazaki T, Leonor N, Taniguchi T, Fujita T, Kanakura Y, Komiya S, Yoshimura A (1997). „A new protein containing an SH2 domain that inhibits JAK kinases”. Nature387 (6636): 921–4. DOI:10.1038/43213. PMID9202126.
↑Pezet A, Favre H, Kelly PA, Edery M (1999). „Inhibition and restoration of prolactin signal transduction by suppressors of cytokine signaling”. J. Biol. Chem.274 (35): 24497–502. DOI:10.1074/jbc.274.35.24497. PMID10455112.
↑Takahashi-Tezuka M, Hibi M, Fujitani Y, Fukada T, Yamaguchi T, Hirano T (1997). „Tec tyrosine kinase links the cytokine receptors to PI-3 kinase probably through JAK”. Oncogene14 (19): 2273–82. DOI:10.1038/sj.onc.1201071. PMID9178903.
↑Yamashita Y, Watanabe S, Miyazato A, Ohya Ki, Ikeda U, Shimada K, Komatsu N, Hatake K, Miura Y, Ozawa K, Mano H (1998). „Tec and Jak2 kinases cooperate to mediate cytokine-driven activation of c-fos transcription”. Blood91 (5): 1496–507. PMID9473212.
↑Guo D, Dunbar JD, Yang CH, Pfeffer LM, Donner DB (1998). „Induction of Jak/STAT signaling by activation of the type 1 TNF receptor”. J. Immunol.160 (6): 2742–50. PMID9510175.
↑Shigematsu H, Iwasaki H, Otsuka T, Ohno Y, Arima F, Niho Y (1997). „Role of the vav proto-oncogene product (Vav) in erythropoietin-mediated cell proliferation and phosphatidylinositol 3-kinase activity”. J. Biol. Chem.272 (22): 14334–40. DOI:10.1074/jbc.272.22.14334. PMID9162069.
Berger R (2006). „[A recurrent mutation of the JAK2 gene in chronic myeloproliferative disorders]”. Pathol. Biol.54 (4): 182–4. DOI:10.1016/j.patbio.2005.07.002. PMID16084028.
Pargade V, Darnige L, Gaussem P (2006). „[Acquired mutation of JAK2 tyrosine kinase and polycythaemia vera]”. Ann. Biol. Clin. (Paris)64 (1): 3–9. PMID16420986.
Staerk J, Kallin A, Royer Y i dr.. (2007). „JAK2, the JAK2 V617F mutant and cytokine receptors”. Pathol. Biol.55 (2): 88–91. DOI:10.1016/j.patbio.2006.06.003. PMID16904848.
Hsu HC (2007). „Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders”. Journal of the Chinese Medical Association : JCMA70 (3): 89–93. DOI:10.1016/S1726-4901(09)70337-5. PMID17389152.